Drug Profile
Research programme: idiopathic pulmonary fibrosis therapeutic - Celdara Medical/Pulmatrix
Alternative Names: CM Y JH01; CM-Y-JH01 dry powder - Celdara Medical/PulmatrixLatest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Celdara Medical; Pulmatrix
- Developer Celdara Medical; Pulmatrix; University of Vermont
- Class Biological factors; Biological proteins
- Mechanism of Action Epithelial cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in USA (Inhalation, Powder)
- 02 Oct 2015 Preclinical trials in Idiopathic pulmonary fibrosis in USA (Inhalation), before October 2015